Showing 1 - 20 results of 112,005 for search '(( 5 _ decrease ) OR ((( 50 mm decrease ) OR ( 10 ((we decrease) OR (nn decrease)) ))))', query time: 0.75s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

    mGluR5 receptor decreased glycinergic currents. by Zi-Yang Zhang (4988555)

    Published 2019
    “…(<b>E</b>) The inhibitory effect of CHPG on GlyR-IPSCs was not blocked by intracellularly loaded GDP-β-S (62.3 ± 6.4% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.782, <i>p</i> = 0.032), chelerythrine (60.9 ± 11.3% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.705, <i>p</i> = 0.035), or Ro-32-0432 (69.9 ± 3.2% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 8.495, <i>p</i> < 0.001). (<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …”
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    Image 5_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

    Published 2025
    “…Moreover, 5 of the decreased autoantibodies can also be applied for supervising bone metastasis in lung adenocarcinoma. …”
  17. 17
  18. 18

    Characteristic of decreased bacterial diversity in psoriasis by Tong Su (425712)

    Published 2022
    “…Significant differences of gut microbiome profiles were revealed in murine model with psoriasis by sequencing 16S rRNA V3-V4 variable region. Group comparisons included the imiquimod cream (IMQ group, n=8), the imiquimod cream and antibiotics (ATB) (PC+IMQ group, n=8) and the healthy control (CTRL group, n=8). …”
  19. 19
  20. 20

    Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

    Published 2024
    “…<p>Cell lysates were obtained from THP-1 monocytes exposed to reagents as indicated: Lane 1, vehicle; Lane 2, PARP inhibitor olaparib (5 mM, 24 hr); Lane 3, oxLDL (100 mg/mL, 24 hr) or Lane 4, combination of oxLDL and olaparib. …”